SIRT1在卵巢浆液性肿瘤中的表达及临床意义

Clinical significance and expression of SIRT1 in ovarian serous tumors

目的：检测组蛋白去乙酰化酶（SIRT1）在卵巢浆液性腺癌中的表达情况,探索其在卵巢浆液性腺癌发生、扩散过程中的作用。方法：采用免疫组化SP二步法检测SIRT1在卵巢浆液性腺瘤15例、卵巢交界性浆液性腺瘤15例、卵巢浆液性腺癌45例（低分化15例、中分化15例、高分化15例,FIGO分期I~IV期,其中I期4例、II期8例、III期14例、IV期19例）中的表达。结果：卵巢浆液性腺瘤组、卵巢交界性浆液性腺瘤组、卵巢浆液性腺癌组（低分化、中分化、高分化）中SIRT1阳性表达率依次为6.7%、40.0%、68.9%（86.7%、73.3%、46.7%）;卵巢浆液性腺癌组织分化水平越低,SIRT1阳性表达率越高,SIRT1在卵巢浆液性腺瘤组中的表达与卵巢浆液性腺癌组和卵巢交界性浆液性腺瘤组相比拟,差异均具有统计学意义（P〈0.05）;SIRT1在卵巢浆液性腺癌组的不同临床期别中表达无明显差异,不具有统计学意义（P〉0.05）。结论：卵巢浆液性腺癌组织中SIRT1呈高表达,提示了恶性程度高其可能与卵巢浆液性腺癌细胞的繁殖、生长有着密切的关系。

Objective To detect the expression of SIRT1 in ovarian serous adenocarcinoina,and to explore its role in the occur- rence and transfer process of ovarian serous adenocarcinoma. Methods The expression of SIRT1 in 15 cases of ovarian serous eystadeno- ma, 15 cases of borderline ovarian serous cystadenoma and 45 eases of ovarian serous adenocareinoma （differentiation of low, medium and high differentiation all 15 eases,FIGO stage I ~ IV,among them 4 eases were in stage 1,8 eases were in stage II,14 cases were in stage III and 19 eases were in stage IV） were examined by immunohistochemical staining （SP）. Results The positive rate for SIRT1 expression in the ovarian serous eystadenoma group was 6.7% ,the borderline ovarian serous eystadenoma group was 40.0% ,and the ovarian serous ade- nocarcinoma groups was 68.9% （differentiation of low, medium and high differentiation were respectively 86.7% ,73.3% and 46.7% ） ; The positive expression rate of SIRT1 was higher in the lower level tissue differentiation of ovarian serous adenocareinoma. The expressions of SIRTI in the ovarian serous adenoeareinoma groups and the borderline ovarian serous eystadenoma group were significantly higher than those in the borderline ovarian serous eystadenoma group and there were significant different （ P 〈 0.05 ）. The expressions of SIRT1 in dif- ferent clinical stages of ovarian serous adenocareinoma has no obvious difference （P 〉 0.05 ）. Conclusion SIRT1 is high expression in o- varian serous carcinoma. And SIRT1 may be related to the breeding and growth of the ovarian serous gland cancer cells.